Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics’ proprietary Tumor Glycoform specific scFv discovery platform and CiMaas’s Adoptive CAR-NK technology.
By entering into a research collaboration with an option for an exclusive commercial license for its antibody structures (specific directed against underglycosylated Mucin-1 and potentially other candidates) to CiMaas, the Technical University of Denmark (DTU) and CiMaas have strengthened their relation to fight cancer.